Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymax’s Omontys Recalled After Deaths; Uncertain Future Ahead For Company

This article was originally published in The Pink Sheet Daily

Executive Summary

Affymax and its partner Takeda recalled all of their ESA product after rare but unexplained patient fatalities, leaving both the product’s and the company’s future in limbo. The safety concerns may fuel fears about the unknowns of biologic production.

Advertisement

Related Content

Emerging Markets Earnings Roundup: Astra Zeneca and Teva (Part 6)
Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
Reimbursement of Biosimilar and Biosimilar-similar ESAs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel